Qiagen has launched the EZ2 Connect MDx IVD platform for automated sampling in diagnostic laboratories.

The company is offering the platform for widescale use 18 months after it was made available for research.

The EZ2 Connect MDx device has a high degree of automation and enables laboratories to perform parallel purification of DNA and RNA from up to 24 samples in 30 minutes.

Available in Canada, the US and other countries, the platform has EU CE-IVD compliance marking for in-vitro devices (IVD) for the European Union and other countries accepting this designation.

Qiagen Molecular Diagnostics Business Area head and senior vice-president Jean-Pascal Viola said: “EZ2 Connect MDx puts standardised and efficient nucleic acid purification in reach of any clinical lab.

“It solves the challenges of many clinical diagnostics labs that have to provide diagnostics results quickly, that have to deal with fluctuating sample numbers as well as a large variety of sample types and quality.”

EZ2 Connect MDx uses magnetic-bead technology to extract nucleic acids from serum, blood plasma, stool and other sample types.

It features prefilled and sealed reagent cartridges for process safety along with integrated cameras for load checking.

Other features of the device include on-board pipetting and heating, UV decontamination, and automated piercing of the sealed cartridge.

Designed to handle a range of sample materials, EZ2 Connect MDx complements the company’s offering of automated IVD nucleic extraction platforms, which includes QIAsymphony and QIAcube Connect MDx.

EZ2 Connect MDx can be used with research kits (MBA) in research mode or with EZ1 DSP kits in dedicated IVD mode along with protocols for diagnostic workflows.

It can also use the QIAsphere digital laboratory ecosystem for complete integration into the digital infrastructure of a lab, enabling remote instrument management.

Additionally, the platform combines process safety, ease of use and the EZ1’s robustness with improved throughput and digital features.

Last September, Qiagen and Neuron23 signed an agreement to develop a next-generation sequencing (NGS) companion diagnostic (CDx) for the latter’s brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor to treat Parkinson’s disease.